Recombinant anti-osteopontin antibody and use thereof

Details for Australian Patent Application No. 2002332290 (hide)

Owner Astellas Pharma Inc. Juridical Foundation the Chemo-sero-therapeutic Research Institute

Inventors Nakashima, Toshihiro; Uede, Toshimitsu; HIGUCHI, Hirofumi; Tokieda, Yoshiyuki; Maeda, Hiroaki; Kon, Shigeyuki; TORIKAI, Masaharu; YAMAMOTO, Nobuchika

Agent Davies Collison Cave

Pub. Number AU-B-2002332290

PCT Number PCT/JP02/09868

PCT Pub. Number WO2003/027151

Priority 2001-290700 25.09.01 JP

Filing date 25 September 2002

Wipo publication date 7 April 2003

Acceptance publication date 8 November 2007

International Classifications

C07K 16/18 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - against material from animals or humans

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 19/02 (2006.01) Drugs for skeletal disorders

A61P 29/00 (2006.01) Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents

A61P 37/00 (2006.01) Drugs for immunological or allergic disorders

A61P 37/02 (2006.01) Drugs for immunological or allergic disorders

C07K 14/52 (2006.01) Peptides having more than 20 amino acids

C07K 16/24 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C12N 15/13 (2006.01) Mutation or genetic engineering - Immunoglobulins

C12N 15/63 (2006.01) Mutation or genetic engineering - Introduction of foreign genetic material using vectors

C12P 21/08 (2006.01) Preparation of peptides or proteins - Monoclonal antibodies

A61K 39/00 (2006.01) Medicinal preparations containing antigens or antibodies

Event Publications

6 February 2003 Complete Application Filed

  Priority application(s): 2001-290700 25.09.01 JP

26 June 2003 Application Open to Public Inspection

  Published as AU-B-2002332290

2 March 2006 Assignment before Grant

  Immuno-Biological Laboratories Co., Ltd.; Fujisawa Pharmaceutical Co., Ltd The application has been assigned to Immuno-Biological Laboratories Co., Ltd.; Astellas Pharma Inc.

30 November 2006 Assignment before Grant

  Immuno-Biological Laboratories Co; Ltd The application has been assigned to Astellas Pharma Inc.; Juridical Foundation the Chemo-sero-therapeutic Research Institute

8 November 2007 Application Accepted

  Published as AU-B-2002332290

6 March 2008 Alteration of Name

  The name of the patentee has been altered to Juridical Foundation The Chemo-Sero-Therapeutic Research Institute; Astellas Pharma Inc.

6 March 2008 Standard Patent Sealed

23 April 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002332291-CONNECTOR FOR HIGH-RATE TRANSMISSION

2002332289-Diaryl sulfide derivative, addition salt thereof, and immunosppressant